AnGes 

AnGes, Inc., a biopharmaceutical firm established in 1999 and headquartered in Ibaraki, Japan, specializes in the research and advancement of gene-based medical solutions. The company's flagship product is Hepatocyte Growth Factor (HGF) Plasmid, a pioneering gene therapy developed to address critical limb ischemia, a severe condition characterized by impaired blood circulation in the legs. Beyond its lead therapy, AnGes is progressing a diverse portfolio of treatments. This includes NF-kB Decoy Oligonucleotide, a nucleic acid medicine designed to mitigate inflammation, which is being investigated for ailments such as low back pain. The company is also working on therapies for atopic dermatitis and disc degeneration, alongside medical devices aimed at preventing vascular restenosis. Their efforts extend to the vaccine sector, encompassing therapeutic vaccines for cervical intraepithelial neoplasia (a precursor to cervical cancer), and DNA vaccines for high blood pressure, developed through a collaboration with Osaka University. Furthermore, AnGes is involved in multiple initiatives for coronavirus vaccines, including a partnership with Osaka University and an investigational plasmid DNA vaccine project with Brickell Biotech, Inc., targeting markets in the United States, South America, and elsewhere. To expand its commercial reach and development capabilities, AnGes has forged several strategic alliances. It collaborates with BioMarin Pharmaceutical Inc. for the Japanese marketing of Naglazyme, a drug for mucopolysaccharidosis VI. AnGes also partners with Mitsubishi Tanabe Pharma Corporation to market HGF Plasmid for peripheral arterial disease in the U.S. and Japan. Other key partnerships include SHIONOGI & CO., LTD. for the distribution of external-use drugs containing NF-kB decoy oligonucleotide for skin conditions, and Vical, Inc. for the development and commercialization of Allovectin, a cancer treatment. The company, originally known as AnGes MG, Inc., officially adopted the name AnGes, Inc. in July 2017, continuing its commitment to innovation in gene-based medicine.